Prostate cancer
Conditions
Interventions
Radiotherapy with 62 Gy delivered at 3.1 Gy/fraction
Sponsors
Department of Radiation Oncology, Graduate School of Medical and Dental Sciences, Niigata University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Patients with performance status(ECOG) of 0 or 1. 2) Patients with histologically confirmed prostate adenocarcinoma. 3) T1-T3aN0M0 4) Patients who give a written informed consent obtained.
Exclusion criteria
Exclusion criteria: 1) Patients who received radiotherapy for prostate. 2) Patients who received surgery for prostate. 3) Patients with uncontrolled active infection. 4) Cancer patients with a duplication of activity. 5) Patients with serious complications (uncontrollable collagen disease, heart disease, pulmonary disease, liver disease). 6) Mental diseases which prevent from registration of this trial. 7) Patients who received chemotherapy for prostate cancer. 8) Patients with inflammatory bowel disease. 9) Patients with severe or uncontrollable diabetes mellitus. 10) Risk organs are too close to the PTV to keep dose constraints. 11) Patients judged inappropriate for this study by the physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of 2-year late adverse events | — |
Countries
Japan
Contacts
Public ContactEisuke Abe
Niigata University Graduate School of Medical and Dental Sciences Department of Radiation Oncology
Outcome results
None listed